Carol A Langford
The Cleveland Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carol A Langford as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:25 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04474847 · Abatacept for the Treatment of Giant Cell ArteritisUniversity of Pennsylvania · recruiting · Giant Cell Arteritis · principal investigator
- Ph3NCT02108860 · Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)University of South Florida · completed · Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis · principal investigator
- Ph2NCT00556439 · Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's ArteritisNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · completed · Takayasu's Arteritis, Giant Cell Arteritis · principal investigator
- Ph1/Ph2NCT00468208 · Abatacept in Treating Adults With Mild Relapsing Wegener's GranulomatosisUniversity of Pennsylvania · completed · Wegener's Granulomatosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- RITUXIMAB THERAPY FOR THE INDUCTION REMISSION AND TOLERANCE IN ANCA-ASSOCIATEM01RR018390 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · fiscal years 2007 · $10,126 awarded in 2007Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Vasculitis Clinical Research Consortium (VCRC)U54AR057319 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Peter A Merkel · fiscal years 2009 to 2020Named on NCT02108860, NCT00468208
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:25 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med · 20102,080 citationsRCR 63.1
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.N Engl J Med · 2017815 citationsRCR 37.5
- Efficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med · 2013571 citationsRCR 20.0
- A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.Arthritis Rheumatol · 2017250 citationsRCR 10.2
- Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Ann Rheum Dis · 2016202 citationsRCR 8.8
- A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.Arthritis Rheum · 2012164 citationsRCR 5.9
- A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.Arthritis Rheum · 1999159 citationsRCR 5.7
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.J Am Soc Nephrol · 2015140 citationsRCR 6.1
- 131 citationsRCR 4.1
- Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.Arthritis Rheum · 2004127 citationsRCR 4.0